biostudies-literatureUnknown6(12)Shankar B<h4>Importance</h4>The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, and their development is associated with improved patient survival across tumor types. The spectrum and impact on survival for patients with non-small cell lung cancer (NSCLC) who develop multisystem irAEs from ICIs, has not been described.<h4>Objective</h4>To characterize multisystem irAEs, their association with survival, and risk factors for multisystem irAE development.<h4>Design, setting, and participants</h4>This retrospective cohort study carried out in 5 academic institutions worldwide included 623 patients with stage III/IV NSCLC, treated with anti-PD-(L)JAMA oncology1952-1956https://www.ebi.ac.uk/biostudies/studies/S-EPMC7596677biostudies-literatureMultisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.PMC7596677Sugawara SOtterson GANaidoo JBrahmer JRZhang JFeliciano JLPatel SHWalker PForde PMNaqash ARShankar BRicciuti BMarrone KAToi YHann CLEttinger DSOwen DfalseMultisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.<h4>Importance</h4>The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, and their development is associated with improved patient survival across tumor types. The spectrum and impact on survival for patients with non-small cell lung cancer (NSCLC) who develop multisystem irAEs from ICIs, has not been described.<h4>Objective</h4>To characterize multisystem irAEs, their association with survival, and risk factors for multisystem irAE development.<h4>Design, setting, and participants</h4>This retrospective cohort study carried out in 5 academic institutions worldwide included 623 patients with stage III/IV NSCLC, treated with anti-PD-(L)2020-01-01T00:00:00Z2020 Dec2025-04-04T14:15:10.029Z2025-04-04T14:15:10.029ZS-EPMC75966773311903410.1001/jamaoncol.2020.5012